Knowledge regarding the potential mode of action of stromal cells in the treatment of endometrial disorders, such as AS, remains scarce, and therefore, we made the informed choice to not narrow down the cell product to a specific subpopulation, e.g., the endometrial pericyte: platelet-derived growth factor receptor beta (PDGF-Rβ)+/CD146+ or Sushi Domain Containing 2 (SUSD2)+, as we cautiously cannot exclude that the heterogeneous composition would be part of the therapeutic effect [3, 22, 42, 43]. This evidence concerns the gene PDGFRB and endometrial disorder.